Related Experiment Video
Updated: May 12, 2026
06:55
Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging
Published on: May 11, 2014
Biomarker Use in Barrett's Esophagus Surveillance.
Annesha Chatterjee1, Julian A Abrams2, Matthew D Stachler1
1Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
The American Journal of Gastroenterology
|February 12, 2026
Summary
Barrett's esophagus (BE) patients need better risk assessment for esophageal cancer progression. Biomarkers like p53, genomic content, and methylated DNA show promise in identifying high-risk individuals, overcoming limitations of dysplasia assessment.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Diagnostics
Background:
- Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma, but most patients do not progress.
- Current risk stratification relies on dysplasia assessment, which suffers from significant inter-observer variability.
- There is a critical need for reliable biomarkers to identify BE patients at high risk of cancer progression.
Purpose of the Study:
- To review promising biomarkers for predicting progression risk in Barrett's esophagus.
- To highlight the limitations of current dysplasia assessment in clinical practice.
- To summarize research on p53, abnormal genomic content, and methylated DNA markers.
Main Methods:
- Review of studies investigating biomarkers for Barrett's esophagus progression.
- Focus on molecular markers including p53 protein expression.
- Analysis of genomic instability and DNA methylation patterns as predictive markers.
Main Results:
- p53 abnormalities show potential as a marker for increased cancer risk in BE.
- Abnormal genomic content (aneuploidy) is associated with higher progression rates.
- Methylated DNA markers are emerging as promising predictors of esophageal adenocarcinoma development.
Conclusions:
- Biomarkers such as p53, genomic content, and methylated DNA offer improved risk stratification for BE patients.
- These molecular markers can potentially overcome the subjectivity of dysplasia grading.
- Further validation of these biomarkers is crucial for clinical implementation in managing BE.
Related Concept Videos
01:21Barrett Esophagus-I: Introduction
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...